drugset / Trial / NCT04044651
Lenvatinib Plus Nivolumab Versus Lenvatinib for Advanced Hepatocellular Carcinoma With Hepatitis B Virus Infection
Phase 2/3
Withdrawn
Shi Ming
First Affiliated Hospital, Sun Yat-Sen University · collabGuangdong Provincial People's Hospital · collabGuangzhou No.12 People's Hospital · collabThird Affiliated Hospital, Sun Yat-Sen University · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to investigate the efficacy and safety of lenvatinib plus nivolumab compared with lenvatinib monotherapy for patients with advanced hepatitis B virus infection-related hepatocellular carcinoma.
Timeline
- Start
- 2019-10-30
- Primary completion
- 2021-03-30
- Completion
- 2022-09-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lenvatinib | Small molecule | 8 mg | Oral |
| Subject | Lenvatinib | Small molecule | 12 mg | Oral |
| Subject | Nivolumab | Monoclonal antibody | 480 mg | Intravenous |